IL2 and neuroblastoma: Given the absence of a beneficial effect by adding sc-IL-2 to an 8 h infusion of dinutuximab beta [12], the standard treatment recommended by SIOPEN is dinutuximab beta with isotretinoin for maintenance therapy of high-risk neuroblastoma.